Patent ID: 11932671
Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A  C

Claim 1:
2. The polypeptide of claim 1, wherein:
i. the amino acid sequence of the mutant v2 fHbp polypeptide further differs from SEQ ID NO: 5 by substitution at one or more of L123, V124, 5125, G126, L127 and/or G128; where the substitution(s) are selected from the group consisting of: L123R; V124I; S125G or S125T; G126D; L127I; G128A; and/or
ii. the amino acid sequence of the mutant v3 fHbp polypeptide further differs from SEQ ID NO: 17 by substitution at L126, where the substitution is L126R.